Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bristol-Myers Squibb CoBMY -0.79%75 EV-to-EBITDA is 10.99 as of Jul. 30, 2026, which is 18% below its 10-year median of 13.45. GuruFocus rates BMY with a GF Score™ of 75/100 and a GF Value™ of $55.08 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 745 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 57.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bristol-Myers Squibb Co's enterprise value is $164,831 Mil.
Bristol-Myers Squibb Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $14,998 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-EBITDA for today is 10.99.
The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-EBITDA or its related term are showing as below:
BMY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.62 Med: 13.45 Max: 51.9
Current: 10.99
During the past 13 years, the highest EV-to-EBITDA of Bristol-Myers Squibb Co was 51.90. The lowest was 6.62. And the median was 13.45.
BMY's EV-to-EBITDA is ranked better than 57.05% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.91
vs BMY: 10.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Bristol-Myers Squibb Co (NYSE:BMY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bristol-Myers Squibb Co's PE Ratio (TTM) for today is calculated as:
Bristol-Myers Squibb Co's share price for today is $63.10.
Bristol-Myers Squibb Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-EBITDA falls into.
Bristol-Myers Squibb Co's current Enterprise Value is $164,831 Mil.
Bristol-Myers Squibb Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,998 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (BMY) has a EV-to-EBITDA of 10.99 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bristol-Myers Squibb Co. This is 18% below median its historical median of 13.45. Over the past decade, Bristol-Myers Squibb Co's EV-to-EBITDA has ranged from 6.62 to 51.90. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #320 out of 745 companies in the Drug Manufacturers industry, placing it in the top 43%.
Is Bristol-Myers Squibb Co's EV-to-EBITDA too high?
Bristol-Myers Squibb Co's current EV-to-EBITDA of 10.99 is 18% below median its 10-year median of 13.45. Over the past 10 years, this metric has ranged from a low of 6.62 to a high of 51.90. The Drug Manufacturers industry median EV-to-EBITDA is 12.91. Bristol-Myers Squibb Co's value of 10.99 is 14.9% below this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #320 out of 745 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's EV-to-EBITDA compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #320 out of 745 companies for EV-to-EBITDA. This puts Bristol-Myers Squibb Co in the upper half of its industry. The industry median EV-to-EBITDA is 12.91. Bristol-Myers Squibb Co's value of 10.99 is 14.9% below this benchmark. Historically, Bristol-Myers Squibb Co's own EV-to-EBITDA has ranged from 6.62 to 51.90 over the past decade. While the company's 10-year median is 13.45 vs. the industry median of 12.91, Bristol-Myers Squibb Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.91, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current EV-to-EBITDA of 10.99 is 14.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bristol-Myers Squibb Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current EV-to-EBITDA is 10.99, which is 18% below median its own 10-year median of 13.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $55.08, compared to a current price of $63.10 — trading 14.6% above its estimated fair value. The current EV-to-EBITDA is 10.99, which is 18% below median its 10-year median of 13.45 and 14.9% below the Drug Manufacturers industry median of 12.91. Bristol-Myers Squibb Co's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BMY), the current EV-to-EBITDA is 10.99 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $63.10 is trading 14.6% above its estimated GF Value™ of $55.08.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for BMY:
EV-to-EBITDA: 10.99 (18% below median its 10-year median of 13.45)
GF Value™: $55.08 vs. price of $63.10 (14.6% above fair value)
Industry Position: 14.9% below the Drug Manufacturers median (#320 of 745)
No single metric tells the full story. See the BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
75GF Score
Get the complete analysis for BMY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMY has been successfully added to your 
